Related Experiment Video
Updated: Jul 18, 2025
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.7K
Metformin as a promising target for DPP4 expression: computational modeling and experimental validation
Amr Ahmed El-Arabey1, Haiyan Zhang2, Mohnad Abdalla2,3
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, 11751, Egypt. amrel_arabey@azhar.edu.eg.
Medical Oncology (Northwood, London, England)
|August 25, 2023
Summary
Metformin may improve health by targeting Dipeptidyl-peptidase 4 (DPP4) in cancers. This study used computational methods to explore metformin-DPP4 interactions and DPP4
Area of Science:
- Biochemistry
- Computational Biology
- Oncology
Background:
- Metformin is a widely used, affordable medication.
- Dipeptidyl-peptidase 4 (DPP4) is implicated in various clinical disorders.
- Targeting DPP4 is a potential therapeutic strategy.
Purpose of the Study:
- To investigate the molecular interactions between metformin and DPP4 using computational methods.
- To analyze the clinical significance of DPP4 expression and mutations in malignancies.
- To explore the role of DPP4 in immune cell infiltration within the tumor microenvironment.
Main Methods:
- In silico molecular docking and dynamic modeling to assess metformin-DPP4 interactions.
- Bioinformatic analysis of DPP4 expression, mutation data, and immune cell invasion in cancer.
Main Results:
- Identified potential binding sites and interaction dynamics between metformin and DPP4.
- Highlighted the association of DPP4 expression and mutations with various cancer types.
- Correlated DPP4 activity with immune cell infiltration in the tumor microenvironment.
Conclusions:
- Metformin's interaction with DPP4 suggests a potential mechanism for its anti-cancer effects.
- DPP4 is a clinically relevant target in oncology.
- Understanding metformin-DPP4 interactions could lead to novel cancer treatment strategies.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
01:24Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358